Immunotoxins are potent bacterial toxins fused to antibodies that bind tumour-specific antigens, and can dramatically improve the clinical utility of some anti-tumour antibodies. This review describes the construction and efficacy of several recombinant immunotoxins, using results from recent clinical trials.
- Ira Pastan
- Raffit Hassan
- Robert J. Kreitman
